Heinz Ludwig, MD, Wilhelminen Cancer Research Institute, Wilhelminenspital, Vienna, Austria, talks on maintenance strategies for patients with myeloma. Prof. Ludwig highlights the use of lenalidomide as the standard maintenance treatment, commenting on overall survival benefits, as well as outlining the use of carfilzomib and daratumumab. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.